Du Min, Su Xiao-Mei, Zhang Tao, Xing Yong-Jun
Department of Oncology, PLA General Hospital of Chengdu Military Region, Chengdu, Sichuan 610083, P.R. China.
Affiliated Stomatological Hospital, PLA General Hospital of Chengdu Military Region, Chengdu, Sichuan 610083, P.R. China.
Mol Med Rep. 2014 Aug;10(2):1051-5. doi: 10.3892/mmr.2014.2276. Epub 2014 May 27.
Bone morphogenetic protein 2 (BMP2) is a growth factor that is involved in the development and progression of various types of cancer. However, the epigenetic regulation of the expression of BMP2 and the association between BMP2 expression and drug resistance in breast cancer remains to be elucidated. The present study reported that the expression of BMP2 was significantly decreased in primary breast cancer samples and the MCF‑7/ADR breast cancer mulitdrug resistance cell line, which was closely associated with its promoter DNA methylation status. The expression of BMP2 in MCF‑7/ADR cells markedly increased when treated with 5‑Aza‑2'‑deoxycytidine. Knockdown of BMP2 by specific small interfering RNA enhanced the chemoresistance of the MCF‑7 breast cancer cell line. These findings indicated that epigenetic silencing of BMP2 in breast cancer may be involved in breast cancer progression and drug resistance, and provided a novel prognostic marker and therapeutic strategy for breast cancer.
骨形态发生蛋白2（BMP2）是一种生长因子，参与多种类型癌症的发生和发展。然而，BMP2表达的表观遗传调控以及BMP2表达与乳腺癌耐药性之间的关联仍有待阐明。本研究报告称，原发性乳腺癌样本和MCF-7/ADR乳腺癌多药耐药细胞系中BMP2的表达显著降低，这与其启动子DNA甲基化状态密切相关。用5-氮杂-2'-脱氧胞苷处理时，MCF-7/ADR细胞中BMP2的表达明显增加。通过特异性小干扰RNA敲低BMP2可增强MCF-7乳腺癌细胞系的化疗耐药性。这些发现表明，乳腺癌中BMP2的表观遗传沉默可能参与乳腺癌的进展和耐药性，并为乳腺癌提供了一种新的预后标志物和治疗策略。
